ArticleTissue engineering and regenerative medicine2026
MSC-Derived Small Extracellular Vesicles Alleviate Renal Fibrosis in Hyperuricemic Nephropathy via Suppression of Epithelial Mesenchymal Transition.
Article in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHyperuricemic nephropathy (HN) arises from excessive accumulation of uric acid, leading to subsequent renal injury. Mesenchymal stem cells-derived small extracellular vesicles (MSC-sEVs) have demonstrated beneficial effects in promoting tissue repair across various injury models. However, their potential therapeutic role in HN remains unknown.
methodsWe isolated and characterized MSC-sEVs by transmission electron microscopy, nanoparticle tracking analysis, and Western blotting. A rat model of HN was established by daily administration of adenine and potassium oxonate for three weeks, after which MSC-sEVs were intravenously injected. Renal function, histopathological changes, and fibrotic markers were assessed, while the involvement of epithelial-mesenchymal transition (EMT) was examined both in vivo and in UA-treated HK-2 cells. Regenerative and anti-fibrotic outcomes were examined through Masson's trichrome staining and immunohistochemistry (α-SMA).
resultsRats with HN exhibited significant renal dysfunction and marked interstitial fibrosis. MSC-sEVs treatment significantly improved renal function, as evidenced by reduced serum creatinine and blood urea nitrogen, and attenuated tubulointerstitial fibrosis, collagen deposition, and α-SMA expression in HN rats. Mechanistically, UA induced a classic EMT phenotype in renal tubular cells in vivo and in vitro, characterized by downregulation of E-cadherin and upregulation of N-cadherin and vimentin, all of which were markedly reversed by MSC-sEVs. Notably, miRNA sequencing revealed that MSC-sEVs are enriched in multiple miRNAs that have been previously reported to target EMT-associated signaling pathways, suggesting a potential miRNA-mediated mechanism.
conclusionOur study found that MSC-sEVs can effectively reverse renal EMT in HN, thereby promoting the restoration of renal function, revealing a possible mechanism by which MSC-sEVs treatment in renal fibrosis associated with HN. Taken together, this study provides a foundation for innovative therapeutic approaches and advanced pharmacological strategies for HN.
Indexed as
Identifiers
42878785What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.